The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use
Autor: | Ruth E. Brown, Stephanie C. Manson, Annamaria Cerulli, Carlos Fernandez Vidaurre |
---|---|
Rok vydání: | 2009 |
Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty medicine.drug_class Cost-Benefit Analysis Economic Drug Administration Schedule Pulmonary Disease Chronic Obstructive Adrenal Cortex Hormones Epidemiology medicine Humans Corticosteroids Anti-Asthmatic Agents Adverse effect Intensive care medicine Treatment history Asthma business.industry Incidence (epidemiology) Public health medicine.disease Glucocorticosteroids Surgery Steroid use Adverse events Corticosteroid business |
Zdroj: | Respiratory Medicine. 103(7):975-994 |
ISSN: | 0954-6111 |
DOI: | 10.1016/j.rmed.2009.01.003 |
Popis: | SummaryOral corticosteroids (OCS) are a key part of therapy regimens for a diverse variety of conditions. Despite their efficacy, they are associated with a wide variety of adverse events. The purpose of this review was to identify the range of adverse events that have been reported to be related to oral corticosteroids, examine the factors that influence their incidence and estimate the economic burden caused by these adverse events. In 61 identified studies, 21 different categories of OCS related adverse events were reported with increased fracture risk being the category most frequently described. Most studies that examined factors linked to the incidence of OCS related adverse events found that dose, age, gender, duration of use, treatment history, smoking habits or cholesterol level were influential in determining risk. Additionally, a cumulative economic analysis of selected adverse events found the annual cost of treating these events in the UK to be at least £165 per patient taking OCS. The clinical and economic burden of OCS related adverse events highlights the need for OCS sparing therapies to be developed. |
Databáze: | OpenAIRE |
Externí odkaz: |